VOR BIOPHARMA INC (VOR:NASDAQ)
$19.14 -0.61 (-3.0886%)
Analysed VOR BIOPHARMA INC (VOR:NASDAQ) News Sources
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
14-05-2026
yahoo.com
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely
15-05-2026
yahoo.com
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
28-05-2026
yahoo.com
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
30-05-2026
fool.com
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
30-05-2026
fool.com
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
08-06-2026
yahoo.com
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
08-06-2026
yahoo.com
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next
30-06-2026
yahoo.com
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02-07-2026
yahoo.com
Vor Bio Appoints David Zaccardelli to Board of Directors
07-07-2026
yahoo.com
What is the current price of VOR BIOPHARMA INC (VOR:NASDAQ)?
The current price of VOR BIOPHARMA INC (VOR:NASDAQ) is $19.14.
VOR BIOPHARMA INC (VOR:NASDAQ) absolute price change since previous trading day?
The absolute price change of VOR BIOPHARMA INC (VOR:NASDAQ) since the previous trading day is $-0.61.
VOR BIOPHARMA INC (VOR:NASDAQ) percentage price change since previous trading day?
The percentage price change of VOR BIOPHARMA INC (VOR:NASDAQ) since the previous trading day is -3.0886%.
What is the most recent average sentiment score for VOR BIOPHARMA INC (VOR:NASDAQ)?
The most recent average sentiment score for VOR BIOPHARMA INC (VOR:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for VOR BIOPHARMA INC (VOR:NASDAQ)?
The most recent sentiment for VOR BIOPHARMA INC (VOR:NASDAQ) is .
SEC-8K** Filing Available For VOR BIOPHARMA INC (VOR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.